ReviewRSC advances2026
Lighting up cancer: latest discoveries in ruthenium(ii) polypyridyl complexes for anticancer photodynamic therapy.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT), which utilises light-sensitive compounds to specifically target cancer cells while preventing harm to neighbouring healthy tissues, presents a potentially viable alternative treatment option. Ruthenium (Ru) polypyridyl complexes have garnered considerable attention as prospective PDT agents owing to their capability to generate stable and selective molecules by structural modification through ligands replacement. Additionally, their intricate geometries and oxidation states contribute to their therapeutic potential. This review provides the evolution and application of Ru(ii) polypyridyl complexes in PDT as a cancer treatment modality. It analyses the efficacy, mechanisms of action, and advancements of these complexes in comparison to conventional methods. We present the design and optimisation of these complexes, emphasising their critical importance in combination therapies to circumvent the shortcomings of existing PDT methods and achieve enhanced therapeutic outcomes. Our review subsequently examines the practical implications of the results, highlighting the need for further
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.